Блог
Последни новини, научни статии и полезна информация за молекулярната онкологична диагностика и персонализираната терапия.
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations --...
Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy
Author summary We investigated how N6-methyladenosine (m6A), a prevalent RNA chemical modification, influences non-small cell lung cancer (NSCLC) progression and explored whether natural compounds from the medicinal plant Pueraria could target these pathways.…
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results…
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today an…
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE...
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates....
Страница 4 от 13 • Общо 75 статии